Results 131 to 140 of about 146,874 (392)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer [PDF]

, 2012
PMCID: PMC3446380This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided ...
A Borg, AC Wolff, Adrian Harris, C Wright, DA Budwit-Novotny, DJ Slamon, DJ Slamon, E Tagliabue, EA Musgrove, EHR Perez, G Arpino, G Konecny, GD Lewis Phillips, Georges Sumo, IL Andrulis, Isabel Pinhel, Ivana Sestak, J Cuzick, J Vandesompele, JA Sparano, Jack Cuzick, Janine Salter, JC Brase, JM Harvey, Judith M Bliss, M Dowsett, M Dowsett, M Harigopal, Margaret Hills, ME Hammond, MF Press, Mitch Dowsett, MJ Ellis, MJ Ellis, MJ Piccart-Gebhart, N Quenel, P Royston, Peter Barrett-Lee, RL Camp, Roger A'Hern, S Drury, S Johnston, S Paik, SJ Houston, SS Badve, Suzanne Drury, The Adjuvant Breast Cancer Trials Collaborative Group, V Guarneri, VS Perez   +48 more
core   +5 more sources

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

British Journal of Cancer, 2019
The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in ...
F. Hunter, H. R. Barker, B. Lipert, F. Rothé, G. Gebhart, M. Piccart-Gebhart, C. Sotiriou, S. Jamieson   +7 more
semanticscholar   +1 more source

Harnessing Synergies between Combinatorial Microfluidics and Machine Learning for Chemistry, Biology, and Fluidic Design

Chemistry–Methods, EarlyView.
This review explores the synergy of combinatorial microfluidics and machine learning, highlighting their transformative impact on high‐throughput experimentation, closed‐loop reaction optimization, and autonomous platform development. Key applications in chemical synthesis, biological research, and microfluidic design are discussed, addressing ...
Suyash S. Damir, Julie Probst, Andrew deMello, Stavros Stavrakis   +3 more
wiley   +1 more source

Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial

Cancer Treatment and Research Communications
Aim: To assess the safety and tolerability of subcutaneous (SC) trastuzumab (Herceptin) administered either with a single-use injection device (SID) or manually from a vial using a hand-held syringe.
Dilyara Kaidarova, Edvard Zhavrid, Oxana Shatkovskaya, Aliaksandr Prokharau, Nina Akhmed, Dauren Sembayev, Zhanna Rutzhanova, Alexandr Ivankov   +7 more
doaj   +1 more source

Decoding anthracycline- and trastuzumab-related cardiac dysfunction prediction: HFA-ICOS scores versus strain imaging. [PDF]

ESC Heart Fail
Left ventricular global longitudinal strain (LV‐GLS) is the best tool for predicting CTRCD due to anthracycline and trastuzumab. Abstract Aims Baseline Heart Failure Association–International Cardio‐Oncology Society (HFA‐ICOS) scores and serial left ventricular global longitudinal strain (LV‐GLS) measurements have been found to be useful in predicting ...
Nguyen HH, Giang NM, Vo DT, Ho THQ, Ngoc-Hoa C.   +4 more
europepmc   +2 more sources

Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. [PDF]

, 2020
The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019.
Chan, Alexandre, Ke, Yu, Tan, Chia Jie
core  

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]

, 2017
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David, Gatalica, Zoran, Heestand, Gregory M, Kurzrock, Razelle, Schwaederle, Maria   +4 more
core   +1 more source

RETRACTED ARTICLE: Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer

Cell Death and Disease, 2020
Trastuzumab is commonly used in the treatment of human epidermal growth factor receptor-2 positive (HER-2+) breast cancer, but its efficacy is often limited by the emergence of chemoresistance.
Mingli Han, Jianguo Hu, Pengwei Lu, H. Cao, Chao Yu, Xiang-ke Li, Xueke Qian, Xue Yang, Yunqing Yang, N. Han, Dong-wei Dou, Fan Zhang, Mulin Ye, Changcheng Yang, Yuanting Gu, Huaying Dong   +15 more
semanticscholar   +1 more source

Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults

Clinical Pharmacology &Therapeutics, EarlyView.
Wang et al.1 (2009) and Zhang et al.2 (2011) recommended a fixed dosing approach for large molecule therapeutics for first‐in‐human (FIH) trials, based on the finding that the majority of α values (body size effect on clearance) were < 0.5 across 12 monoclonal antibodies (mAbs) and 18 therapeutic proteins (TPs) and peptides, and fixed dosing provides ...
Andrew B. SyBing, Huili Chen, Diane D. Wang   +2 more
wiley   +1 more source

Recommendations for HER2 testing in the UK [PDF]

, 2000
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease.
Bartlett, J., Cooke, T., Dowsett, M., Ellis, I.O., Gullick, W., Gusterson, B., Lee, P.B., Mallon, E., Walker, R.   +8 more
core   +2 more sources